To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:Subscribe to Hematology/Oncology Clinics
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cancer statistics, 2019.CA Cancer J Clin. 2019; 69: 7-34
- Prostate cancer (version 1.2019).(Available at:)Accessed January 15, 2019)
- Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options.J Urol. 2018; 199: 683-690
- Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.J Clin Oncol. 2018; (JCO1800606. [Epub ahead of print])
- Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options.J Urol. 2018; 199: 990-997
- Active surveillance for prostate cancer: a systematic review of the literature.Eur Urol. 2012; 62: 976-983
- The role of prevalence in the diagnosis of prostate cancer.Cancer Control. 2006; 13: 158-168
- Landmarks in prostate cancer.Nat Rev Urol. 2018; 15: 627-642
- The diagnosis and treatment of prostate cancer: a review.JAMA. 2017; 317: 2532-2542
- Comparative effectiveness of minimally invasive vs open radical prostatectomy.JAMA. 2009; 302: 1557-1564
- A systematic review of the volume-outcome relationship for radical prostatectomy.Eur Urol. 2013; 64: 786-798
- Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial.JAMA Oncol. 2018; 4: e180039
- A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.Eur Urol. 2013; 64: 895-902
- Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.Cancer. 2015; 121: 2713-2719
- Conventional versus hypofractionated radiation therapy for localized prostate cancer: a meta-analysis of randomized noninferiority trials.Eur Urol Focus. 2019; 5: 577-584
- Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer.J Clin Oncol. 2018; 36: 2943-2949
- Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of GETUG 14 randomized trial.J Clin Oncol. 2016; 34(Suppl 15)
- Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial.Eur Urol. 2018; 74: 432-441
- Androgen deprivation in prostate cancer--step by step.N Engl J Med. 2009; 360: 2572-2574
- Androgen deprivation therapy: a survival benefit or detriment in men with high-risk prostate cancer?.Oncology (Williston Park). 2010; 24 (798): 790-796
- Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.Int J Radiat Oncol Biol Phys. 2017; 98: 275-285
- ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.Int J Radiat Oncol Biol Phys. 2017; 98: 286-295
- Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer.JAMA. 2018; 319: 896-905
- Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG oncology RTOG 0521 trial.J Clin Oncol. 2019; 37: 1159-1168
- A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: results of SPCG-13 trial.J Clin Oncol. 2018; 36: 5000
- An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.Int J Radiat Oncol Biol Phys. 2007; 69: 646-655
- Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study.Int J Radiat Oncol Biol Phys. 2016; 96: 759-769
- Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.Radiology. 2011; 259: 852-861
- Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis.Eur Urol. 2017; ([pii:S0302-2838(17)30697-8])
- Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.J Clin Oncol. 2014; 32: 3939-3947
- Castration-resistant prostate cancer: locking up the molecular escape routes.Clin Cancer Res. 2009; 15: 3251-3255
- Newly diagnosed metastatic prostate cancer: has the paradigm changed?.Urol Clin North Am. 2017; 44: 611-621
- A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?.World J Urol. 2019; ([pii:S0302-2838(17)30697-8])
- Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial.Int J Radiat Oncol Biol Phys. 2018; 102: S3-S4
- Declining use of radiotherapy for adverse features after radical prostatectomy: results from the National Cancer Data Base.Eur Urol. 2015; 68: 768-774
- Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer.N Engl J Med. 2017; 376: 417-428
- Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.Lancet Oncol. 2016; 17: 747-756
- Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG oncology/RTOG 0534 SPPORT trial.Int J Radiat Oncol Biol Phys. 2018; 102: 1605
- Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the Scandinavian Prostate Cancer Group-7.Eur Urol. 2016; 70: 684-691
Published online: October 28, 2019
Disclosure Statement: The authors have nothing to disclose.
© 2019 Elsevier Inc. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- ErratumHematology/Oncology ClinicsVol. 34Issue 2
- PreviewFor the article on “Radiation Therapy for Prostate Cancer” in the February 2020 issue of Hematology/Oncology Clinics of North America (Volume 34, Issue 1), a few errors occurred regarding the mentions of the Tables. On page 48, a mention of Table 1 was erroneously placed in the section, “Intermediate-Risk Disease”. On page 51, a mention of Table 1 was erroneously placed in the section, “Definition and historical perspective”. Also on page 51, at the end of the section, “Definition and historical perspective”, the mention of Table 6 was incorrectly labeled as Table 7.